Searle & CO. Makes New $112,000 Investment in Oculis Holding AG (NASDAQ:OCS)

Searle & CO. bought a new stake in Oculis Holding AG (NASDAQ:OCS) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,000 shares of the company’s stock, valued at approximately $112,000.

Several other hedge funds have also recently made changes to their positions in OCS. Wolverine Asset Management LLC bought a new stake in shares of Oculis in the third quarter valued at $77,000. Compagnie Lombard Odier SCmA raised its stake in shares of Oculis by 47.3% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock valued at $1,053,000 after purchasing an additional 30,750 shares during the period. Finally, abrdn plc bought a new stake in shares of Oculis during the 4th quarter valued at $15,980,000. 22.30% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on OCS shares. HC Wainwright decreased their price objective on Oculis from $29.00 to $28.00 and set a “buy” rating on the stock in a research note on Wednesday, April 24th. Robert W. Baird decreased their price objective on Oculis from $64.00 to $35.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 19th. Wedbush reiterated an “outperform” rating and set a $29.00 price objective on shares of Oculis in a research note on Wednesday, March 6th. Finally, Chardan Capital restated a “buy” rating and issued a $30.00 target price on shares of Oculis in a research note on Tuesday, March 19th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $29.14.

Oculis Price Performance

OCS opened at $12.85 on Thursday. The stock has a 50-day moving average price of $11.87 and a 200-day moving average price of $11.28. Oculis Holding AG has a 12-month low of $9.05 and a 12-month high of $14.50. The company has a current ratio of 5.29, a quick ratio of 5.29 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Monday, March 18th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.04. The firm had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.28 million. As a group, equities analysts expect that Oculis Holding AG will post -1.72 EPS for the current year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.